IFF Announces Further Evolution of its Board of Directors
27.2.2023 14:55:00 EET | Business Wire | Press release
IFF (NYSE: IFF) today announced the next phase of the evolution of its Board of Directors, to support the ongoing execution of the company’s strategic transformation and long-term financial vision.
Kevin O’Byrne, Chief Financial Officer and director of J Sainsbury Plc, has been appointed to join the IFF Board, effective March 10, 2023. O’Byrne is an established financial executive with decades of experience driving sustainable growth and overseeing transformation strategies for international consumer retail businesses. He brings to IFF a deep understanding of the consumer landscape and evolving expectations of CPG customers, which will be valuable to IFF as it continues to execute on its customer-centric and growth-focused strategy. O’Byrne will serve on the Board’s Audit, Innovation, and Transaction Committees.
IFF also announced that Edward (Ed) Breen and Matthias Heinzel, both of whom have served as directors and members of the Board’s Innovation Committee since 2021, have notified IFF of their respective decisions to retire from the Board. Breen and Heinzel will not stand for reelection at IFF’s 2023 Annual Meeting of Shareholders. In addition, Stephen Williamson, director since 2017 and a member of the Board’s Audit Committee, has notified IFF of his decision to retire from the Board effective March 10, 2023.
“On behalf of the entire Board, I would like to thank Ed, Stephen and Matthias for their many contributions to IFF,” said Dale Morrison, Chair of the IFF Board. “As directors, each has helped oversee the development of IFF’s refreshed growth strategy as we’ve become an even stronger partner for customers across the global value chain for consumer goods and commercial products. It has been an honor to work alongside these three leaders and I wish them all the best in their next chapters.”
“It has been a privilege to serve on the IFF Board as the company has established itself as the industry’s premier partner through the transformative combination of DuPont’s Nutrition and Biosciences business,” said Ed Breen, Director of the IFF Board. “Both the IFF Board and leadership team have taken strong action to position the company for long-term profitable growth and significant value creation, and I look forward to seeing all that IFF will accomplish in the future.”
“As we continue to evolve our Board of Directors, I am thrilled to welcome Kevin as an incoming director,” said Roger Ferguson, Incoming Chair of the IFF Board. “Kevin brings more than 30 years of retail and consumer goods experience to the IFF Board and a proven track record overseeing numerous multinational finance initiatives and successful business integrations. I am confident that his expertise and international perspective will be critical as we capture new growth opportunities, execute on our productivity initiatives and optimize our portfolio.”
O’Byrne is responsible for the finance, strategy, property, procurement and investor relations functions at J Sainsbury Plc, the second largest retailer in the United Kingdom. He will be retiring from Sainsbury's on March 4, 2023. Prior to joining J Sainsbury Plc, he served as Chief Executive Officer of Poundland Group Plc and held various leadership positions at Kingfisher Plc, including Divisional Director UK, China and Turkey, as well as Chief Executive Officer of B&Q UK & Ireland and Group Finance Director.
O’Byrne sits on the Board of Centrica Plc, the leading energy supply and in-home servicing provider in the UK and Ireland. He has chaired the Audit and Risk Committee since May 2019 and is the Senior Independent Director (SID). O’Byrne sat on the board of Land Securities Group Plc, the UK’s largest listed real estate group, for nine years where he chaired the Audit Committee and was SID.
“I am thrilled to join the IFF Board during such an exciting time for the company,” said Kevin O’Byrne, Incoming IFF Director. “IFF continues to lead the industry in delivering innovative solutions that meet the needs of today’s customers, and the company has a clear opportunity to realize its full potential. I look forward to partnering with Roger and the rest of the Board to help IFF become an even stronger industry leader, while driving sustainable, profitable growth.”
Welcome to IFF
At IFF (NYSE: IFF), an industry leader in food, beverage, scent, health and biosciences, science and creativity meet to create essential solutions for a better world – from global icons to unexpected innovations and experiences. With the beauty of art and the precision of science, we are an international collective of thinkers who partners with customers to bring scents, tastes, experiences, ingredients and solutions for products the world craves. Together, we will do more good for people and planet. Learn more at iff.com, Twitter, Facebook, Instagram, and LinkedIn.
© 2023 by International Flavors & Fragrances Inc. IFF is a Registered Trademark. All Rights Reserved.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230226005174/en/
Contact information
Media Relations:
Paula Heinkel
332.877.5339
Media.request@iff.com
Investor Relations:
Michael Bender
212.708.7263
Investor.Relations@iff.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
